Celldex (CLDX) AI Stock Analysis

• Market Cap: $1.41B
• Dividend Yield: N/A
• Average Volume (3M): 1.15M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: 24.49%
• EPS Growth: 5.14%
• Country: US
• Employees: 186
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.81
• Shares Outstanding: 66,394,240
• 10 Day Avg. Volume: 1,125,527
• 30 Day Avg. Volume: 1,150,956
• PEG Ratio: 0.75
• Price to Book (P/B): 1.94
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.92
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 41.01
• Enterprise Value/Gross Profit: 226.72
• Enterprise Value/Ebitda: -1.83
• 1Y Price Target: $54.29
• Price Target Upside: 145.55% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 52 Neutral
• Price Target: $21.50 ▼(-2.76%Downside)

Celldex's overall score is driven by a strong balance sheet and positive corporate events, counterbalanced by financial struggles and poor valuation metrics. Technical indicators suggest some positive momentum, but the company faces challenges with profitability and cash flow management.

Positive Factors

Efficacy

Barzolvolimab's efficacy continues to impress in the treatment of angioedema with an 86% mean reduction from baseline in AAS7 for patients.

Market Opportunity

Barzolvolimab’s unique mast cell-depleting mechanism offers a differentiated, first-in-class profile that stands to unlock significant commercial opportunity in urticaria and other mast cell-driven diseases.

Safety Profile

Barzolvolimab administration is safe and well tolerated with side effects reported as rare, mild, and reversible.

Negative Factors

Market Competition

Barzolvolimab's ability to differentiate itself in an increasingly crowded space adds to its potential market value but poses a challenge due to significant existing competition.

Treatment Challenges

The current CSU treatment paradigm has a strong unmet need, represented by the high rate of poor disease control with currently available treatments.

Celldex Business Overview & Revenue Model

Company Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

How the Company Makes Money

Celldex makes money primarily through the development and eventual commercialization of its drug candidates. The company's revenue model includes licensing agreements, collaboration partnerships, and milestone payments from larger pharmaceutical companies that it partners with during the drug development process. Revenue is also generated from government grants and research funding, which support clinical trials and research initiatives. Upon successful approval and commercialization of its drugs, Celldex anticipates revenue from product sales in the oncology market. Strategic partnerships and collaborations are integral to its financial model, as these alliances provide essential funding and shared resources for developing and marketing its therapeutic products.

Celldex Financial Statement Overview

Summary

Celldex shows moderate revenue growth but struggles with substantial losses indicated by negative net income and EBIT margins. Despite a strong balance sheet with a high equity ratio and low debt, cash flow is challenged with significant negative free cash flow, reflecting operational cash burn.

Income Statement

Celldex shows modest revenue growth with a 7.7% increase in the most recent TTM period. However, the company is struggling with substantial losses, as evidenced by negative net income and EBIT margins. The gross profit margin remains positive at 78.6%, but the net profit margin is significantly negative at -2366.6%, indicating the company is not yet profitable. The biotechnology industry often experiences prolonged periods of negative earnings due to high R&D expenses.

Balance Sheet

The balance sheet is relatively strong with a high equity ratio of 95.1%, which denotes a solid capital structure. The debt-to-equity ratio is very low at 0.005, suggesting minimal leverage. Despite these strengths, the company is facing consistent net losses, impacting its return on equity, which stands at -25.4% in the TTM period.

Cash Flow

Celldex's cash flow is challenged, with a negative free cash flow of -$171.9 million in the TTM period. The operating cash flow to net income ratio is slightly positive at 0.96, indicating some alignment with reported losses. However, the free cash flow to net income ratio is negative, reflecting operational cash burn. Positive financing cash flow suggests reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.56M	7.02M	6.88M	2.36M	4.65M	7.42M
Gross Profit	5.94M	7.02M	3.88M	957.00K	1.58M	-35.12M
EBITDA	-213.94M	-191.90M	-139.03M	-104.20M	-66.08M	-45.64M
Net Income	-178.85M	-157.86M	-141.43M	-122.78M	-70.51M	-59.78M
Balance Sheet
Total Assets	739.47M	792.34M	465.63M	352.74M	444.65M	235.84M
Cash, Cash Equivalents and Short-Term Investments	673.29M	725.28M	423.60M	304.95M	408.25M	194.42M
Total Debt	3.43M	3.81M	2.54M	4.03M	3.04M	3.48M
Total Liabilities	36.49M	45.34M	36.46M	26.53M	25.18M	26.48M
Stockholders Equity	702.98M	747.00M	429.17M	326.20M	419.48M	209.36M
Cash Flow
Free Cash Flow	-171.92M	-159.70M	-109.11M	-105.56M	-62.16M	-41.96M
Operating Cash Flow	-171.51M	-157.78M	-107.29M	-103.73M	-60.91M	-40.40M
Investing Cash Flow	68.03M	-290.13M	-105.78M	89.94M	-216.16M	-98.22M
Financing Cash Flow	5.54M	441.45M	218.46M	4.08M	272.37M	171.23M

Celldex Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 22.11
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDX, the sentiment is Positive. The current price of 22.11 is above the 20-day moving average (MA) of 20.73, above the 50-day MA of 20.23, and below the 200-day MA of 24.00, indicating a neutral trend. The MACD of 0.34 indicates Negative momentum. The RSI at 60.12 is Neutral, neither overbought nor oversold. The STOCH value of 60.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLDX.

Celldex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	74 Outperform	$1.05B	16.36	21.57%	―	25.92%	―
Sector *	64 Neutral	¥343.99B	10.61	-2.88%	2.57%	11.80%	-6.84%
CLDX	52 Neutral	$1.41B	―	-23.20%	―	24.49%	5.14%
WVE	50 Neutral	$1.01B	―	-105.50%	―	-7.06%	-57.17%
SNDX	48 Neutral	$758.94M	―	-93.70%	―	―	-25.83%
IOVA	48 Neutral	$581.05M	―	-51.85%	―	11070.12%	32.07%
DYN	43 Neutral	$986.63M	―	-64.01%	―	―	14.93%

Celldex Corporate Events

Celldex Approves Equity Plan Amendment and Elects New Director

On June 5, 2025, Celldex Therapeutics held its Annual Meeting of Stockholders, where several key decisions were made, including the approval of an amendment to the 2021 Omnibus Equity Incentive Plan, increasing the shares available for issuance by 2,000,000. Additionally, Denice M. Torres was elected to the Board of Directors, bringing extensive leadership experience from the pharmaceutical and consumer healthcare sectors. The election of new board members and the amendment to the equity plan are expected to bolster Celldex’s strategic growth and operational capabilities as it advances its clinical programs, particularly with the promising drug barzolvolimab.

The most recent analyst rating on (CLDX) stock is a Buy with a $74.00 price target. To see the full list of analyst forecasts on Celldex stock, see the CLDX Stock Forecast page.